Is Regeneron Stock a Buy After a Regulatory Blow?
Biotech giant Regeneron (NASDAQ: REGN) has been an outstanding performer over the past year. And although its stock is still up by 20% in the trailing-12-month period, the company's shares recently took a significant blow, dropping by 8% in one day. For a company the size of Regeneron -- with a market capitalization of $78.7 billion -- that's a massive one-day dip.
Regeneron suffered this blow following a regulatory obstacle, as is often the case in the biotech industry (more on that below). Do these developments represent an excellent opportunity to buy Regeneron's shares on the dip? Or should investors stay away from the company? Let's find out.
Source Fool.com
Regeneron Pharmaceuticals Inc. Stock
€994.80
0.380%
With 45 Buy predictions and 1 Sell predictions Regeneron Pharmaceuticals Inc. is one of the favorites of our community.
As a result the target price of 1034 € shows a slightly positive potential of 3.94% compared to the current price of 994.8 € for Regeneron Pharmaceuticals Inc..
